Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CUL1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CUL1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CUL1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CUL1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CUL1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CUL1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CUL1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
GO:007093617 | Esophagus | ESCC | protein K48-linked ubiquitination | 55/8552 | 65/18723 | 8.42e-11 | 2.58e-09 | 55 |
GO:00065136 | Esophagus | ESCC | protein monoubiquitination | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
GO:000008214 | Esophagus | ESCC | G1/S transition of mitotic cell cycle | 134/8552 | 214/18723 | 4.04e-07 | 5.55e-06 | 134 |
GO:004484314 | Esophagus | ESCC | cell cycle G1/S phase transition | 148/8552 | 241/18723 | 5.68e-07 | 7.48e-06 | 148 |
GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
GO:00311461 | Esophagus | ESCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
GO:00431617 | Liver | NAFLD | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/1882 | 412/18723 | 3.00e-13 | 1.75e-10 | 91 |
GO:00104987 | Liver | NAFLD | proteasomal protein catabolic process | 101/1882 | 490/18723 | 1.35e-12 | 6.09e-10 | 101 |
GO:00002095 | Liver | NAFLD | protein polyubiquitination | 51/1882 | 236/18723 | 1.04e-07 | 8.10e-06 | 51 |
GO:00709364 | Liver | NAFLD | protein K48-linked ubiquitination | 19/1882 | 65/18723 | 1.33e-05 | 3.97e-04 | 19 |
GO:00458606 | Liver | NAFLD | positive regulation of protein kinase activity | 65/1882 | 386/18723 | 2.22e-05 | 6.13e-04 | 65 |
GO:00336747 | Liver | NAFLD | positive regulation of kinase activity | 74/1882 | 467/18723 | 5.16e-05 | 1.19e-03 | 74 |
GO:0044772 | Liver | NAFLD | mitotic cell cycle phase transition | 67/1882 | 424/18723 | 1.25e-04 | 2.39e-03 | 67 |
GO:0044843 | Liver | NAFLD | cell cycle G1/S phase transition | 43/1882 | 241/18723 | 1.40e-04 | 2.63e-03 | 43 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412019 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0411014 | Prostate | BPH | Cell cycle | 49/1718 | 157/8465 | 7.39e-04 | 3.59e-03 | 2.22e-03 | 49 |
hsa0471011 | Prostate | BPH | Circadian rhythm | 15/1718 | 34/8465 | 1.40e-03 | 5.85e-03 | 3.62e-03 | 15 |
hsa0435012 | Prostate | BPH | TGF-beta signaling pathway | 35/1718 | 108/8465 | 1.98e-03 | 7.92e-03 | 4.90e-03 | 35 |
hsa05170110 | Prostate | BPH | Human immunodeficiency virus 1 infection | 60/1718 | 212/8465 | 2.96e-03 | 1.12e-02 | 6.92e-03 | 60 |
hsa0431015 | Prostate | BPH | Wnt signaling pathway | 50/1718 | 171/8465 | 3.11e-03 | 1.15e-02 | 7.14e-03 | 50 |
hsa0414129 | Prostate | Tumor | Protein processing in endoplasmic reticulum | 99/1791 | 174/8465 | 2.58e-25 | 1.71e-23 | 1.06e-23 | 99 |
hsa0513129 | Prostate | Tumor | Shigellosis | 94/1791 | 247/8465 | 5.56e-10 | 9.69e-09 | 6.01e-09 | 94 |
hsa0435021 | Prostate | Tumor | TGF-beta signaling pathway | 39/1791 | 108/8465 | 2.33e-04 | 1.35e-03 | 8.39e-04 | 39 |
hsa0411021 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
hsa0517026 | Prostate | Tumor | Human immunodeficiency virus 1 infection | 62/1791 | 212/8465 | 3.05e-03 | 1.12e-02 | 6.94e-03 | 62 |
hsa0471021 | Prostate | Tumor | Circadian rhythm | 14/1791 | 34/8465 | 6.44e-03 | 2.16e-02 | 1.34e-02 | 14 |
hsa0431023 | Prostate | Tumor | Wnt signaling pathway | 50/1791 | 171/8465 | 7.32e-03 | 2.37e-02 | 1.47e-02 | 50 |
hsa0414137 | Prostate | Tumor | Protein processing in endoplasmic reticulum | 99/1791 | 174/8465 | 2.58e-25 | 1.71e-23 | 1.06e-23 | 99 |
hsa0513137 | Prostate | Tumor | Shigellosis | 94/1791 | 247/8465 | 5.56e-10 | 9.69e-09 | 6.01e-09 | 94 |
hsa0435031 | Prostate | Tumor | TGF-beta signaling pathway | 39/1791 | 108/8465 | 2.33e-04 | 1.35e-03 | 8.39e-04 | 39 |
hsa0411031 | Prostate | Tumor | Cell cycle | 51/1791 | 157/8465 | 5.67e-04 | 2.89e-03 | 1.79e-03 | 51 |
hsa0517036 | Prostate | Tumor | Human immunodeficiency virus 1 infection | 62/1791 | 212/8465 | 3.05e-03 | 1.12e-02 | 6.94e-03 | 62 |
hsa0471031 | Prostate | Tumor | Circadian rhythm | 14/1791 | 34/8465 | 6.44e-03 | 2.16e-02 | 1.34e-02 | 14 |
hsa0431033 | Prostate | Tumor | Wnt signaling pathway | 50/1791 | 171/8465 | 7.32e-03 | 2.37e-02 | 1.47e-02 | 50 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CUL1 | SNV | Missense_Mutation | novel | c.1711N>C | p.Ala571Pro | p.A571P | Q13616 | protein_coding | tolerated(0.27) | benign(0.39) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
CUL1 | SNV | Missense_Mutation | novel | c.1181N>G | p.Ala394Gly | p.A394G | Q13616 | protein_coding | deleterious(0.01) | probably_damaging(0.917) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
CUL1 | SNV | Missense_Mutation | novel | c.1555G>A | p.Glu519Lys | p.E519K | Q13616 | protein_coding | tolerated(0.24) | possibly_damaging(0.514) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CUL1 | SNV | Missense_Mutation | | c.721G>C | p.Glu241Gln | p.E241Q | Q13616 | protein_coding | deleterious(0.02) | possibly_damaging(0.762) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
CUL1 | SNV | Missense_Mutation | novel | c.1660N>T | p.Ala554Ser | p.A554S | Q13616 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CUL1 | SNV | Missense_Mutation | novel | c.1118N>C | p.Val373Ala | p.V373A | Q13616 | protein_coding | deleterious(0.03) | probably_damaging(0.942) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CUL1 | SNV | Missense_Mutation | novel | c.1181C>G | p.Ala394Gly | p.A394G | Q13616 | protein_coding | deleterious(0.01) | probably_damaging(0.917) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
CUL1 | SNV | Missense_Mutation | | c.1549N>G | p.Leu517Val | p.L517V | Q13616 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-BH-A0RX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
CUL1 | SNV | Missense_Mutation | | c.436C>T | p.Arg146Cys | p.R146C | Q13616 | protein_coding | deleterious(0) | benign(0.063) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CUL1 | SNV | Missense_Mutation | novel | c.2110G>C | p.Glu704Gln | p.E704Q | Q13616 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |